Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety and Clinical Tolerability of hdmASIT+TM Administered Subcutaneously in House Dust Mite-induced Allergic Rhinoconjunctivitis Patients

NCT03094845 is registered in ClinicalTrials.gov with ASIT Biotech S.A. as lead sponsor.

NCT NCT03094845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03094845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety and Clinical Tolerability of hdmASIT+TM Administered Subcutaneously in House Dust Mite-induced Allergic Rhinoconjunctivitis Patients
Lead sponsor
ASIT Biotech S.A.
Phase
Phase 2
Overall status
Completed
Start date
September 28, 2016
Completion date
January 23, 2017
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

house dust mite allergy